Oseltamivir: another case of regulatory failure?

@article{Cohen2014OseltamivirAC,
  title={Oseltamivir: another case of regulatory failure?},
  author={Deborah Cohen},
  journal={BMJ : British Medical Journal},
  year={2014},
  volume={348}
}
  • D. Cohen
  • Published 9 April 2014
  • Medicine
  • BMJ : British Medical Journal
Governments around the world stockpiled oseltamivir for a flu pandemic despite uncertainty about its harms. Deborah Cohen investigates what the regulators knew and whether their response was adequate 

The Tamiflu fiasco and lessons learnt

This article takes a comprehensive relook on the Tamiflu saga, and suggests some ways and means to avoid a similar situation in the future.

Financial Conflicts of Interest and Conclusions About Neuraminidase Inhibitors for Influenza

Whether there is an association between financial conflicts of interest and the favorable presentation of evidence in systematic reviews on the use of neuraminidase inhibitors for the prophylaxis and treatment of influenza is determined.

Enhanced inhibition of influenza virus infection by peptide-noble metal nanoparticle conjugates

It is demonstrated that conjugation of FluPep to gold and silver nanoparticles enhances its antiviral potency; the antimicrobial activity of silver ions may enable the design of even more potent anti-microbial inhibitors.

Enhanced inhibition of influenza virus infection by peptide–noble-metal nanoparticle conjugates

It is demonstrated that conjugation of FluPep to gold and silver nanoparticles enhances its antiviral potency; the antimicrobial activity of silver ions may enable the design of even more potent antimicrobial inhibitors, capable of targeting both influenza and bacterial co-infections.

References

SHOWING 1-10 OF 24 REFERENCES

Complications: tracking down the data on oseltamivir

  • D. Cohen
  • Medicine
    BMJ : British Medical Journal
  • 2009
A Cochrane group’s attempt to reproduce an analysis underpinning the use of oseltamivir in pandemic influenza hit a brick wall. Deborah Cohen retraces its steps

Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007–2010

Assessment of oseltamivir safety before and during the 2009 influenza A (H1N1) pandemic using biologically plausible risk intervals, particularly focusing on psychiatric events.

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.

Oseltamivir administered daily for six weeks by the oral route is safe and effective for the prevention of influenza.

USE OF THE SELECTIVE ORAL NEURAMINIDASE INHIBITOR OSELTAMIVIR TO PREVENT INFLUENZA

Oseltamivir administered daily for six weeks by the oral route is safe and effective for the prevention of influenza.

UK scientific adviser criticises UK planning for flu pandemic

  • A. O'dowd
  • Medicine
    BMJ : British Medical Journal
  • 2009
The government’s chief scientific adviser is not convinced that the United Kingdom has the right plans in place to cope with avian flu, but plans to deal with that were appropriate for now.

Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza

The data suggest that oral oseltamivir treatment reduces the duration and severity of acute influenza in healthy adults and may decrease the incidence of secondary complications.

Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships

Following the review of known clinical cases of this type, and in the light of the study of animal experiments and the latest laboratory findings, it is proposed to classify adverse reactions to Tamiflu as follows: Sudden onset adverse reactions typically occurring after taking one or two doses of Tamifflu; these result from the central nervous system suppressant action of oseltamivir.

Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir

This review summarizes the results of a comprehensive assessment of the company’s own preclinical and clinical studies, post-marketing spontaneous adverse event reporting, epidemiological investigations utilizing health claims and medical records databases and an extensive review of the literature on neuropsychiatric abnormalities reported in patients with influenza.

Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey.

The results confirmed anecdotal evidence of poor adherence, provided timely information with which to assist decision-making, and formed part of the body of growing evidence that contributed to policy changes to restrict widespread use of prophylaxis for school contacts of confirmed cases of influenza A(H1N1)v.